A five-year hospital surveillance program in China found that nearly half of clinical isolates were multidrug-resistant, with sharp divergence across pathogen species. Carbapenem-resistant Klebsiella pneumoniae rose and peaked in early 2023, while carbapenem-resistant Pseudomonas aeruginosa climbed in a relentless monthly pattern. The findings underscore that antimicrobial resistance control cannot rely on single headline prevalence metrics. Instead, the study suggests pathogen-specific and time-resolved monitoring is necessary to match infection-control responses to local evolutionary dynamics. For biotech and pharma, the surveillance data serves as a reality check for pipeline planning and for clinical trial site selection in antimicrobial development, where resistance pressure varies over time. The study also supports continued investment in diagnostics and stewardship programs that can quickly detect shifts in resistant strains rather than waiting for annual or aggregate reports.